Product Program year 2025 Source: CMS Open Payments

Pemgarda

Biological Infectious Disease

NDC 81960-031-03

Open in the dashboard

General payments

$440,324

2,537 payments

Research payments

$0

0 payments

Through program year 2025, $440,324 in general payments and $0 in research payments were reported against Pemgarda (Infectious Disease).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

2 rows
Year Kind Amount Payments
2025 General $369,818 2,269
2024 General $70,507 268

Breakdown

Who paid General payments · program years 2024–2025
  1. Invivyd Inc $440,324 2,537 payments
Top recipients General payments · program year 2025
  1. Paul Bolno Stowe, VT $134,351 36% · 3 payments
  2. Robert Gottlieb Advanced Heart Failure and Transplant Cardiology · Dallas, TX $16,790 5% · 14 payments
  3. Cedric Spak Infectious Disease · Fort Worth, TX $9,647 3% · 11 payments
  4. Muhammad Bilal Abid Hospitalist · Milwaukee, WI $9,314 3% · 5 payments
  5. Teena Chopra Infectious Disease · Detroit, MI $8,700 2% · 5 payments

The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2025.

The top 25 recipients, free in the app

Specialties paid General payments · program year 2025
  1. Rheumatology Internal Medicine $40,321 22% · 333 practitioners
  2. Infectious Disease Internal Medicine $38,630 21% · 66 practitioners
  3. Hematology & Oncology Internal Medicine $18,379 10% · 146 practitioners
  4. Advanced Heart Failure and Transplant Cardiology Internal Medicine $16,975 9% · 10 practitioners
  5. Hospitalist $9,434 5% · 3 practitioners

The top 5 of 77 specialties; each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.

The top 25 specialties, free in the app

Where the money went General payments · program year 2025
  1. Vermont $134,384 36% · 3 recipients
  2. Texas $63,733 17% · 178 recipients
  3. California $31,951 9% · 153 recipients
  4. Pennsylvania $22,443 6% · 74 recipients
  5. Florida $19,969 5% · 109 recipients

The top 5 of 44 states; each share is of general payments naming this product in 2025 where a state was reported.

The top 25 states, free in the app

2,537 general

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record